Dovitinib, a potent FGFR multikinase inhibitor, achieved a preclinical anticancer effect in pancreatic cancers with heightened FGFR signaling, suggesting that the efficacy may be most pronounced in cancer cells overexpressing FGFR2. Here, FGFR2 is linked to familial pancreatic carcinoma.